Skip to content

Pain and Bleeding in Subjects With Acute Anal Fissure: Comparative Evaluation of Three Treatments

Pain and Bleeding in Subjects With Acute Anal Fissure: Comparative Evaluation of Three Treatments

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03355846
Acronym
PBSAAF
Enrollment
99
Registered
2017-11-28
Start date
2018-05-01
Completion date
2018-05-01
Last updated
2018-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Anal Fissure

Keywords

Anal Fissure, local therapy, pain, defecation, bleeding

Brief summary

Starting from the observation that acute anal fissure (AAF) in 6-8 weeks can heal spontaneously and that some of the commonly used commercial products in clinical practice would seem to be useful, the rationale of the comparative study is to try to identify, in compliance with the protocol of Helsinki (2013), the most effective short-term treatment for the disappearance of pain in defecation and cessation of bleeding, shortening the duration of the healing process and favoring the patient's rapid return to his / her activity, respect for patient safety.

Detailed description

Starting from the observation that anal fissure in 6-8 weeks can heal spontaneously and that some of the commonly used commercial products in clinical practice would seem to be useful, the rationale of the comparative study is to try to identify, in compliance with the protocol of Helsinki (2013), the most effective short-term treatment for the disappearance of pain in defecation and cessation of bleeding, shortening the duration of the healing process and favoring the patient's rapid return to his / her activity, respect for patient safety. The comparative study will be conducted by comparing the following products: * Centella® Complex 1 cps 60 mg per os after meals twice a day for 15 days; * Proctocella® Complex cream to be applied in anal area and anal canal after hygiene treatment for 4 weeks; * Flavonil® 1 cps 300 mg per os after meals twice a day for 15 days; * Flavonil® Cream Cream to be applied in anal region and anal canal after hygiene treatment for 4 weeks; * Rectalgan Mousse cleansing cleanser for anal and perineal region for 4 weeks. Our approach attempts to blend, based on the evidence of the most recent scientific literature, the experience of decades of colonproctologic clinical practice that has a predominantly surgical approach, with the clinical evidence of the Science of Nutrition which has a conservative vision in the treatment of ailments and constipation, a predisposing factor in the pathogenesis of anal fissure, in order to obtain healing without surgery. The control group will receive the traditional basic treatment consisting in the application of lubricated anal dilators of increasing gauge according to predetermined pattern, hygiene and diet. The two groups with which they will be compared for the results will receive, in addition to the foregoing (for controls), or Flavonoids (ProtFlav) or Asian Centella Extract (ProtCent), in the form of local mouth and cream tablets to be applied at the perianal level and possibly in the anal canal with gloved finger, containing the same active principles also administered by mouth.

Interventions

DRUGCentella

after meals twice a day for 15 days

DRUGProctocella

after hygiene treatment for 4 weeks;

DRUGFlavonil® cps

after meals twice a day for 15 days

DRUGFlavonil® Cream

treatment for 4 weeks; .

DRUGRectalgan Mousse

for 4 weeks

Sponsors

University of Roma La Sapienza
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Subjects With Acute Anal Fissure * Collaborative patients able to understand and want;

Exclusion criteria

* Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
time for the disappearance of pain1 monthtime for the disappearance of pain in course of treatment

Secondary

MeasureTime frameDescription
time for the disappearance of bleeding1 monthtime for the disappearance of bleeding in course of treatment

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026